抗TIF1γ IgG2亚型是成人皮肌炎癌症与死亡风险的生物标志物
本研究纳入51例成人抗TIF1γ阳性皮肌炎患者,采用新型定量免疫分析法检测抗TIF1γ自身抗体水平及IgG亚型。结果显示抗TIF1γ IgG2与死亡率(P=0.0011)及随访期间癌症发生(P<0.0001)显著相关,当平均荧光强度>385时对癌症的阳性预测值为100%。多因素分析显示年龄>60岁(P=0.015)和抗TIF1γ IgG2存在(P=0.048)与死亡率独立相关。
要点
- 抗TIF1γ IgG2与癌症发生及死亡率显著相关。
- 抗TIF1γ IgG2平均荧光强度>385时癌症阳性预测值达100%。
- 年龄>60岁和抗TIF1γ IgG2是死亡的独立危险因素。
核心结论
- 抗TIF1γ IgG2是抗TIF1γ阳性皮肌炎患者癌症的潜在新生物标志物,有助于识别死亡风险。
研究设计与样本
- 多中心研究,纳入2013年8月至2017年8月成人抗TIF1γ阳性皮肌炎患者51例,平均年龄61±17岁,男女比0.65。
- 采用新开发的定量免疫分析法检测抗TIF1γ自身抗体水平及IgG亚型。
- 采用Cox比例风险回归模型进行单因素和多因素分析确定危险因素。
主要发现
- 51例患者中40例(78%)患癌症,21例(41%)死亡,平均生存时间10±6个月。
- 抗TIF1γ IgG2检测与死亡率显著相关(P=0.0011),与随访期间癌症发生显著相关(P<0.0001)。
- 抗TIF1γ IgG2平均荧光强度>385时对癌症的阳性预测值为100%。
- 随访24个月后无患者发生癌症。
- 单因素生存分析显示死亡率还与年龄>60岁(P=0.0003)、活动性皮肌炎(P=0.0042)、癌症(P=0.0031)、男性(P=0.011)和CK水平>1,084单位/升(P=0.005)相关。
关键数值与推荐
- 抗TIF1γ IgG2平均荧光强度>385时对癌症的阳性预测值为100%。
- 年龄>60岁(P=0.015)和抗TIF1γ IgG2存在(P=0.048)为死亡的独立相关因素。
临床怎么用
- 对成人抗TIF1γ阳性皮肌炎患者可检测抗TIF1γ IgG2亚型以辅助评估癌症和死亡风险。
- 抗TIF1γ IgG2平均荧光强度>385提示癌症风险极高,阳性预测值达100%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Anti-transcription intermediary factor 1γ (anti-TIF1γ) antibodies are the main predictors of cancer in dermatomyositis (DM). Yet, a substantial proportion of anti-TIF1γ-positive DM patients do not develop cancer. This study was undertaken to identify biomarkers to better evaluate the risk of cancer and mortality in DM. METHODS: This multicenter study was conducted in adult anti-TIF1γ-positive DM patients from August 2013 to August 2017. Anti-TIF1γ autoantibody levels and IgG subclasses were identified using a newly developed quantitative immunoassay. Age, sex, DM signs and activity, malignancy, and creatine kinase (CK) level were recorded. Risk factors were determined by univariate and multivariate analysis according to a Cox proportional hazards regression model. RESULTS: Among the 51 adult patients enrolled (mean ± SD age 61 ± 17 years; ratio of men to women 0.65), 40 (78%) had cancer and 21 (41%) died, with a mean ± SD survival time of 10 ± 6 months. Detection of anti-TIF1γ IgG2 was significantly associated with mortality (P = 0.0011) and occurrence of cancer during follow-up (P < 0.0001), with a 100% positive predictive value for cancer when the mean fluorescence intensity of anti-TIF1γ IgG2 was >385. None of the patients developed cancer after 24 months of follow-up. Univariate survival analyses showed that mortality was also associated with age >60 years (P = 0.0003), active DM (P = 0.0042), cancer (P = 0.0031), male sex (P = 0.011), and CK level >1,084 units/liter (P = 0.005). Multivariate analysis revealed that age >60 years (P = 0.015) and the presence of anti-TIF1γ IgG2 (P = 0.048) were independently associated with mortality. CONCLUSION: Our findings indicate that anti-TIF1γ IgG2 is a potential new biomarker of cancer that should be helpful in identifying the risk of mortality in anti-TIF1γ-positive DM patients.
引用
- Aussy A, Fréret M, Gallay L, et al. The IgG2 Isotype of Anti-Transcription Intermediary Factor 1γ Autoantibodies Is a Biomarker of Cancer and Mortality in Adult Dermatomyositis. Arthritis Rheumatol. 2019. PMID: 30896088. doi:10.1002/art.40895
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。